Upharmacia May 2017
CIS REGION PHARMA
NEWS
EEU
On May 6, the single drug
market was launched within
the Eurasian Economic Union. The national
markets of five member-states (Russia,
Kazakhstan, Belarus, Armenia and Kyrgyzstan)
started operating in a single space format.
Now the development, pre-clinical and clinical
trials, quality control, registration, production
and distribution of medicines will be carried
out under the single norms of the EEU.
However, to make it easier for companies to
adapt to new demands, transitional periods
are envisaged.
— —
K azakhstan
The Head of AIMP
Kazakhstan stated that after
the launch of single drug market within the
Eurasian Economic Union, local drugs may
drop in price 10-15%.
— —
— — On 23/05/2017, the Heads of leading
pharmaceutical associations in Kazakhstan
signed Memorandum of restraining growth
of prices on drugs and medical devices. The
document fixated prices of 105 products.
R ussia
In the next 7 years, BIOCAD
company will invest EUR 25 mio in
the construction of the plant in Turku science
park (Finland). This will become the first step
to enter the EU market.
— —
— — National Immunobiological Company
(NacImBio) signed the contract on cooperation
with Binnopharm company. The companies
plan to establish joint manufacturing of a
multicomponent vaccine with the use of an
10
antihepatitic component.
— — AstraZeneca and Skolkovo Foundation
agreed on strategic partnership in R&D and
education activity. Currently, AstraZeneca
studies the developments of resident
companies of Skolkovo in oncology field,
aiming to find possibilities for cooperation.
— — National pharma distributor SIA Group
acquired 30% share in Bentus Laboratory,
largest Russian producer of household
antiseptics under Sanitelle brand.
— — Nearmedic Group, which includes the clinics
chain and pharmaceutical company, started
searching for a strategical investor. For sale
are only production units of the company
that are engaged in the production of drugs,
diagnostic tests and laboratory equipment.
The company plans to attract about USD 100
mio.
— — Group of companies Marathon Pharma (part
of Marathon Group) acquired the control
package of biopharmaceutical company Fort,
the producer of influenza vaccine Ultrix.
— — National Immunobiological Company
(NacImBio) will build new plant for the
production vaccines in Ufa. The budget will
amount RUB 6 bn.
U zbekistan
President of Uzbekistan
signed the Order on creation of
7 free economic zones, specializing in the
production of pharmaceutical products.
The zones will be opened in Karakalpakstan
(Nukus-pharm), Jizzakh region (Zomin-pharm),
Namangan region (Kosonsoy-pharm), Sirdaryo
region (Sirdaryo-pharm), Surxondaryo Region
(Boysun-pharm) and Tashkent region (Buston-
l ik-pharm and Parkent-pharm).
— —
www.upharma-c.com